Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
The U.K. prime minister prepares to meet his German and French counterparts this week.Europe Politicsread more
Amazon is raising seller fees for thousands of small and medium-sized businesses in France because of a new digital tax passed by the French government.Technologyread more
Ahead of the deadline, U.S. President Donald Trump told reporters that Huawei was a national security threat.Technologyread more
Baidu is gearing up to release its second-quarter earnings on Monday with the market expecting a sharp decline in profit.Technologyread more
Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Stocks in Asia rose on Monday as U.S. Treasury yields bounced higher after plunging last week.Asia Marketsread more
The problem with tanking equities lies elsewhere, writes Michael Ivanovitch, because traders see no end to America's unfolding trade disputes with Europe and China.World Economyread more
Beijing wants to use reforms to support a slowing economy.China Marketsread more
Trump said Cook made a "good case" that it would be difficult for Apple to pay tariffs, when Samsung does not face the same hurdle because much of its manufacturing is in...Technologyread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
Swiss health care giant Roche reported a 7 percent rise in 2018 sales on Tuesday, highlighting strong demand for its new range of medicines.
Group sales climbed to 56.8 billion Swiss francs ($57.2 billion) with net income increasing by 24 percent, which included the benefits from the U.S. tax overhaul in early 2018. This beat an estimate in a Reuters poll which had predicted sales of 56.4 billion Swiss francs.
The firm said it expects revenue to grow in the low-to mid-single digit range this year and predicted that it would further increase its dividend for shareholders. Core operating profit rose by 9 percent on a constant exchange rate basis.
Roche CEO Severin Schwan told CNBC the results were "very strong" and showed "continued strong momentum" for the company. Shares climbed 1.8 percent in early deals on Thursday.
"In 2018, Roche achieved very good growth in both divisions. I am particularly pleased with the very strong demand for our new medicines, delivering significant benefit for patients fighting serious diseases like cancer, multiple sclerosis and haemophilia," he added in a statement.
Its diagnostics division saw revenue grow 7 percent during 2018 with its pharma unit growing by the same amount. It stated that key growth drivers were the new multiple sclerosis medicine Ocrevus and cancer medicines Perjeta, Tecentriq, Alecensa as well as the new haemophilia medicine Hemlibra.
Schwan said new medicines accounted for 90 percent of the firm's sales growth in 2018 and called the Ocrevus launch the "most successful" in the history of Roche.
The U.S., which has seen a greater scrutiny on drug pricing in recent years, is a key market for the pharma side of Roche. Schwan told CNBC's Julianna Tatelbaum that for that market "it's all about the value you provide patients."
"And with our research-driven, innovation-driven strategy I think we are well positioned because we can bring this real benefit to patients. And my experience is, in particular in the U.S., the society is also prepared to reward this kind of innovation. So I am confident that the United States will remain a very attractive market," he said.